DeepMeds develops deep learning software that reduces the dosage of Gadolinium-based contrast agents in MRI scans by up to 80%, enhancing patient safety and minimizing toxicity risks. This technology maintains diagnostic image quality while lowering costs for healthcare providers, addressing the need for safer contrast-enhanced imaging solutions.
Funding
$6.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Gadolinium-based contrast agents (GBCAs) enhance MRI image clarity but carry toxicity risks and can accumulate in brain tissue, especially for patients with kidney issues, children, and pregnant women. This necessitates methods to reduce GBCA dosage while maintaining diagnostic accuracy.
Solution
DeepMeds offers deep learning software that reduces Gadolinium dosage in MRI scans by up to 80% while maintaining diagnostic image quality. The software enhances contrast in reduced-dose images to match full-dose image quality, improving patient safety and reducing healthcare costs. By using AI to optimize contrast enhancement, DeepMeds addresses the need for safer contrast-enhanced medical imaging.
Target Audience
Primary customers are hospitals, clinics, and medical imaging centers seeking to reduce GBCA usage, improve patient safety, and lower costs associated with contrast-enhanced MRI procedures.
Features
- Deep learning algorithm for contrast enhancement in MRI images
- Up to 80% reduction in Gadolinium-based contrast agent (GBCA) dosage
- Maintains diagnostic accuracy with reduced GBCA dosage
- Cost-effective alternative to full-dose contrast-enhanced MRI exams